News + Resources
Overreach in M&A Enforcement: The Impact on Pro-Innovation Deals That Aren’t Ever Pursued
In recent months, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have pursued an increasingly aggressive new approach towards mergers and acquisitions (M&A). Taken together, the Agencies’ recently finalized Merger Guidelines and proposed...
ICYMI – Law360: How Biotech Deals May Help Competition, Despite FTC View
In a recent commentary for Law 360, biopharma expert Michael Kinch and economists Jee-Yonn Lehmann and Frederico Mantovanelli rightly point out that biopharmaceutical mergers and acquisitions (M&A) and other collaborations play an important role in promoting...
Pro-Innovation M&A Allows Life Sciences Innovators to Weather the Significant Costs of R&D
Life sciences companies of all sizes face extended time and cost pressures as they work to bring new medicines to patients, as the average cost of research and development (R&D) can exceed $2.8 billion, and it can take more than 10-15 years to bring a new therapy...
Backgrounder: The Role of M&A Policy in the Life Sciences and its Impacts on Innovation
Mergers and acquisitions allow life sciences companies of all sizes to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. Unfortunately, the latest merger guidelines and proposed premerger notification requirements issued by the Federal Trade Commission (FTC) and Department of Justice (DOJ) reflect a misguided approach that will prevent and deter pro-innovation M&A and disrupt our world-class American life sciences ecosystem.
Changes to HSR Premerger Rules Would Add Unnecessary Financial and Operational Barriers to Pro-Innovation M&A
The Hart-Scott-Rodino (HSR) Act requires companies to report information to the Federal Trade Commission (FTC) and Department of Justice (DOJ) before a planned merger or acquisition (M&A). Under the HSR Act, the agencies enforce premerger reporting requirements...